Efficacy and safety of a single-course of yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin (R)) in patients with relapsed or refractory mantle cell lymphoma (MCL) After/not appropriate for autologous stem CA transplantation (ASCT) - A phase II trial of the

Dokumenttyp:: Meeting Abstract
Autor(en):: Weigert, O; von Schilling, C; Rummel, MJ; Pezzutto, A; Unterhalt, M; Hiddemann, W; Dreyling, M
Titel:: Efficacy and safety of a single-course of yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin (R)) in patients with relapsed or refractory mantle cell lymphoma (MCL) After/not appropriate for autologous stem CA transplantation (ASCT) - A phase II trial of the
Zeitschriftentitel:: Blood
Jahr:: 2005
Band / Volume:: 106
Heft / Issue:: 11
Seitenangaben Beitrag:: 277B-277B
Sprache:: eng
Print-ISSN:: 0006-4971
TUM Einrichtung:: III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
BibTeX

Vorkommen: